Altered Expression of DNA Topoisomerase IIalpha, Ki-67, p53 and p27 in Non-Hodgkin's Lymphoma.
- Author:
Kyeong Min LEE
1
;
Mee Young SOL
;
Hyun Jeong KANG
;
Dong Hoon SHIN
;
Kyung Un CHOI
;
Hwal Woong KIM
;
Jee Yeon KIM
;
Do Youn PARK
;
Chang Hun LEE
Author Information
1. Department of Pathology, College of Medicine, Pusan National University, Busan, Korea. mysol@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
Non-Hodgkin's lymphoma;
Topoisomerase IIalpha;
Protein p53;
Ki-67 antigen;
p27 antigen
- MeSH:
Cell Proliferation;
DNA Topoisomerases, Type I*;
DNA Topoisomerases, Type II;
DNA*;
Humans;
Ki-67 Antigen;
Lymphoma, Non-Hodgkin*
- From:Korean Journal of Pathology
2005;39(5):332-337
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Topoisomerase II (TOPO II) is an enzyme that separates intertwined chromosomes during DNA synthesis by transiently breaking and joining DNA strands. The level of TOP II is one of the determinants of cellular sensitivity to anti-tumor drugs in non-Hodgkin's lymphoma patients. The alpha form of TOPO II has been recently used as a marker of cellular proliferation. High levels of TOPO IIalpha are expressed in aggressive and proliferative tumors. METHODS: This study was designed to evaluate the relationship between TOPO IIalpha expression and clinicopathological parameters including age, gender, the serum LDH level, the serum beta2-microglobulin level and stage, or expressions, of Ki-67, p53 and p27, in non-Hodgkin's lymphoma. We analyzed forty-one biopsied tissue specimens from patients with non-Hodgkin's lymphoma. RESULTS: The expression of TOPO IIalpha increased with the clinical stage and it was correlated with Ki-67 and p53 expressions. However, TOPO IIalpha expression did not have any significant correlation with age, gender, the serum LDH level, the serum 2-microglobulin level and the p27 expression. CONCLUSIONS: TOPO IIalpha expression is a useful marker of cellular proliferation and it may serve as a prognostic factor of a tumor's progression and aggressiveness in non-Hodgkin's lymphomas.
